Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - aesculin, cinchocainhydrochlorid, framycetinsulfat, hydrocortison - rektalsalve

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sanofi a/s - aesculin, cinchocainhydrochlorid, framycetinsulfat, hydrocortison - rektalsalve

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - aesculin, cinchocainhydrochlorid, framycetinsulfat, hydrocortison - rektalsalve

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - aesculin, cinchocainhydrochlorid, framycetinsulfat, hydrocortison - rektalsalve

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alk-abello a/s - hveps - pulver og solvens til injektionsvæske, opløsning - 450.000 sq-u/htgl

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alk-abello a/s - hveps - injektionsvæske, suspension - initialsæt

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - buspironhydrochlorid - tabletter - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

upjohn eesv - tolterodintartrat - depotkapsler, hårde - 2 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

steba biotech s.a - padeliporfin di-kalium - prostatiske neoplasmer - antineoplastiske midler - tookad er angivet som monoterapi til voksne patienter med tidligere ubehandlet, ensidige, lav risiko, adenocarcinom i prostata med en forventet levetid ≥ 10 år og kliniske fase t1c eller t2a;gleason score ≤ 6, der er baseret på high-resolution biopsi strategier, psa ≤ 10 ng/ml;3 positive kræft-kerner med en maksimal kræft længde på 5 mm i en kerne eller 1-2 positiv kræft kerner med ≥ 50 % kræft engagement i en kerne eller en psa massefylde ≥ 0. 15 ng/ml/cm3.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

viatris limited - clopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for yderligere oplysninger henvises der til afsnit 5.